{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-130714","form_type":"8-K","ticker":"ZVRA","cik":"0001434647","company_name":"ZEVRA THERAPEUTICS, INC.","filed_at":"2025-05-29T23:59:59+00:00","discovered_at":"2026-05-14T18:02:48.285343+00:00","generated_at":"2026-05-20T05:41:46.923978+00:00","sec_items":["5.07"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.15,"confidence":"high","headline":"Zevra Therapeutics stockholders elect Dixon and Favorito as Class I directors","bullets":["Wendy Dixon elected with 25.8M for (9.1M withheld); Tamara Favorito with 25.6M for (9.3M withheld). Broker non-votes ~9.65M.","Dissident Mangless failed to comply with Rule 14a-19 and bylaws; his nominees Mickle and Regan disregarded despite 9.2M and 8.4M votes.","Ratification of Ernst & Young as auditor passed: 43.8M for, 360k against, 382k abstain; no broker non-votes.","81.4% of outstanding shares (44.5M of 54.7M) were present or represented at the May 29, 2025 meeting."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-130714","json":"https://secwatch.observer/filing/0001193125-25-130714.json","markdown":"https://secwatch.observer/filing/0001193125-25-130714.md","text":"https://secwatch.observer/filing/0001193125-25-130714.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1434647/000119312525130714/0001193125-25-130714-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1434647/000119312525130714/d54488d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-20T05:41:46.923978+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}